Four Qiming Venture-Backed Biotech Firms Named to 2024 China High-Tech High-Growth Rising Stars in Biopharma

Recently,Qimingpu Releases Rising Stars · 2024 China Biomedical Industry High-Tech High-Growth Enterprise List.The list aims to identify non-listed innovative companies in China's biopharmaceuticals industry with strong growth and good development potential.

Qiming Venture Partners' portfolio companies Shanghai Xinsu Medical Technology Co., Ltd, Yidao Biotechnology(Suzhou) Co., Ltd, Epigenic Therapeutics, Inc., and LTZ Therapeutics Inc. have been selected for the list.

Shanghai Xinsu Medical Technology Co., Ltd., Yidao Biotechnology(Suzhou) Co., Ltd.
Epigenic, LTZ Therapeutics

SELECTED

Rising Star · 2024 China Biomedical Industry
High-Tech High-Growth Enterprise List

Qiming Card pointed out that the advancement of technology and the growing global health demands have made the biopharmaceuticals industry receive widespread attention and rapid development worldwide. This industry covers multiple sectors from basic research to drug development, production, and sales. In terms of industrial structure, a diversified development pattern has been formed, mainly consisting of chemical drugs and biopharmaceuticals.As China's biopharmaceutical industry develops rapidly, it also focuses on the improvement and upgrading of the industrial chain. Currently, China has formed a complete industrial chain ranging from active pharmaceutical ingredient production, formulation processing to sales and services.

With the advancement of technology and the continuous changes in the market, investment and financing activities in the industry will continue to deepen, and China's biopharmaceutical enterprises are gradually moving towards high-end and intelligent development.The competition in China's biopharmaceuticals market is intense, with large enterprises holding advantages in research and development as well as market presence. However, small and medium-sized enterprises are also rapidly emerging, seeking growth opportunities through differentiated competition strategies. Chinese biopharmaceutical companies are continuously increasing their R&D investment, achieving a series of internationally influential results. As product quality and innovation capabilities improve, an increasing number of China-produced biopharmaceutical products are entering the international market, gaining recognition from users worldwide.

Source | Qiming Card